When was Exome Asset Management founded?

Exome Asset Management was founded in 2018.

Where is Exome Asset Management's headquarters located?

Exome Asset Management's headquarters is located in New York City (United States).

How many companies has Exome Asset Management invested in?

Exome Asset Management has invested in 7 companies, including NextCure & Aprea.

Which companies has Exome Asset Management invested in lately?

NextCure & Aprea are the latest investments by Exome Asset Management.

What sectors does Exome Asset Management focus on for investments?

Top sectors in Exome Asset Management's portfolio are Life Sciences (7 investments) and High Tech (1 investment).

What stages of companies does Exome Asset Management typically invest in?

Exome Asset Management primarily invests in Series D and Series G stages.

How many exits has Exome Asset Management been involved in?

Exome Asset Management's portfolio has seen 6 IPOs and 1 acquisition.

Exome Asset Management - 2026 Investor Profile, Portfolio, Team & Investment Trends

Q: How big is Exome Asset Management's investment team?

Exome Asset Management has a team of 7.

Exome Asset Management is a family office founded in 2018. It is primarily based out of New York City, United States. As of Sep 2026, Exome Asset Management is an active investor, having invested in 7 companies, with 1 new investments in the last 12 months. It primarily invests in Post IPO round in United States based companies. Its investments are spread across a wide range of sectors from Life Sciences, High Tech. Its latest investment was a $21.5M Post IPO round in NextCure on Nov 12, 2025, which also saw participation from Ikarian Capital and squadroncap.com.

Overall, Exome Asset Management portfolio has seen 6 IPOs and 1 acquisition including key companies like NextCure, Aprea and Impact Therapeutics. A lot of funds co-invest with Exome Asset Management, with names like Ikarian Capital sharing a substantial percentage of its portfolio.

Exome Asset Management has a team of 7 people including 1 partner.

Key Metrics

Founded Year

2018

Location

New York City, United States

Portfolio Companies

NextCure, Aprea & 5 more

Sectors of Investment

Life Sciences, High Tech & 1 more

Stages of Investment

Post IPO, Series D & 1 more

Locations of Investment

United States, China & 1 more

View Exome Asset Management's full profile

Exome Asset Management has a portfolio of 7 companies. Their most notable investmentis in Zhejiang Nuhui Health TechnologyTheir portfolio spans across United States, China and Sweden. They have invested in Life Sciences, High Tech, Enterprise Applications, across Post IPO, Series D and 1 more. Here is the list of top investments by Exome Asset Management:

1. NextCure

Developer of next-generation immuno-oncology-based drugs. The proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. The pipeline candidates include NC318 for tumor and macrophages, NC410 for myeloid and T-cells, NC762 for tumors, NC252 for leukemia cells, and others.

Key facts about NextCure

Founded Year: 2015
Location: New Haven (United States)
Annual Revenue: $10M - $50M as on Dec 31, 2020
Stage: Public
Total Funding till date: $175M
Employee Count: 54 as on Apr 03, 2025
Investors: ArrowMark Partners, Timefolio Capital and 19 Others
Latest Funding Round: Post IPO, Nov 12, 2025, $*****
Highlight: Public

2. Aprea

Developer of small molecule therapeutics targeting tumor suppressor proteins. The company focuses on p53, a tumor suppressor protein that induces cell cycle arrest or cell death. The company's lead candidate is APR-246, that acts by reactivating mutant and defective native p53, leading to tumor cell death. The company is also developing APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.

Key facts about Aprea

Founded Year: 2003
Location: Boston (United States)
Stage: Public
Total Funding till date: $113M
Investors: ADS Ventures, Janus Henderson Investors and 15 Others
Latest Funding Round: Post IPO, Dec 09, 2025, $*****
Highlight: Public

3. Impact Therapeutics

Developer of small molecule therapeutics for the treatment of cancer. The company's product line include Senaparib is a PARP inhibitor for ovarian cancer maintenance therapy and small cell lung cancer, meeting primary endpoints in the FLAMES study for superior efficacy and safety. Other assets include WEE1 inhibitor IMP7068, ATR inhibitor IMP9064, and PARP1-selective inhibitor IMP1734 (collaborating with Eikon Therapeutics), alongside additional DDR inhibitors.

Key facts about Impact Therapeutics

Founded Year: 2009
Location: Nanjing (China)
Stage: Public
Total Funding till date: $180M
Investors: Decheng Capital, Exome Asset Management and 21 Others
Latest Funding Round: Series D, Nov 15, 2024, $*****
Highlight: Public

4. Broncus

Developer of solutions for diagnosing and treating lung disease. The company has developed the Archimedes navigation bronchoscopy system, which includes BTPNA (Bronchoscopic Trans-Parenchymal Nodule Access) that combines state-of-the-art nodule, vessel, and airway mapping, pathway guidance, and augmented fluoroscopic imaging enabling unprecedented biopsy and therapeutic access to any location in the lung. It also offer InterVapor Bronchoscopic Thermal Vapor Ablation is a non-surgical, non-implant therapy designed to improve lung function.

Key facts about Broncus

Founded Year: 1998
Location: San Jose (United States)
Annual Revenue: $1M - $10M as on Dec 31, 2024
Stage: Public
Total Funding till date: $82.5M
Employee Count: 63 as on Aug 31, 2026
Investors: Western Technology Investment, Saints Capital and 33 Others
Latest Funding Round: Series G, Jan 28, 2021, $*****
Highlight: Public

5. Zhejiang Nuhui Health Technology

Provider of early cancer screening and testing services. The company has developed a fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. The company also has a product for gastric cancer detection through their Helicobacter pylori toxicity factor detection technology. The company leverages its expertise in genetic testing, molecular diagnostics, and large data platforms and software in developing early detection tests for cancer.

Key facts about Zhejiang Nuhui Health Technology

Founded Year: 2013
Location: Beijing (China)
Stage: Public
Total Funding till date: $152M
Employee Count: 501 - 1,000 as on Jul 01, 2024
Investors: Rock Springs Capital, Exome Asset Management and 19 Others
Latest Funding Round: Series E, Jul 10, 2020, $*****
Highlight: Public

View the full list of portfolio companies

Exome Asset Management has invested in 7 companies over the last 6 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 1 investment. Its most recent first time investment was in NextCure.

Here are Exome Asset Management's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	1	0	1
2024	1	0	1
2023	1	0	1
2022	1	0	1
2021	1	0	1
2020	2	0	2

View all investments by Exome Asset Management

Exome Asset Management has made 4 investments in Post IPO stage with an average round size of $31M, 2 investments in Series D stage with an average round size of $20M and 1 investment in Series G stage.

Here are Exome Asset Management's investments by stage:

Stage of entry	No. of Investments
Post IPO	4
Series D	2
Series G	1

Note: We have considered here, only first round of investments

View all investments by Exome Asset Management

Exome Asset Management has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications and High Tech. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 1 Saas company and at least 1 company focusing on Software.

Here are Exome Asset Management's investments by sector:

Sector	No. of Investments
Life Sciences	7
Enterprise Applications	1
High Tech	1

Note: We have considered here, only first round of investments

View all investments by Exome Asset Management

Exome Asset Management has made most investments in United States (4), followed by China where it has made 3 investments.

Here are Exome Asset Management's investments by geography:

Country	No. of Investments
United States	4
China	3
Sweden	1

Note: We have considered here, only first round of investments

View all investments by Exome Asset Management

Exome Asset Management has not made any investment in 2026 so far.

Here are the most recent investments by Exome Asset Management:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Nov 12, 2025	NextCure	United States	Post IPO	1897	Ikarian Capital [+2]
Mar 11, 2024	Aprea	United States	Post IPO	7417	Nantahala Capital Management ... [+3]
Aug 07, 2023	Gracell Bio	China	Post IPO	5298	Vivo Capital [+7]
Mar 14, 2022	Impact Therapeutics	China	Series D	8007	Dingxin Capital [+6]
Jan 28, 2021	Broncus	United States	Series G	9904	FountainVest Partners [+2]

See more recent investments made by Exome Asset Management

6 of Exome Asset Management's portfolio companies have become public. Impact Therapeutics got listed on the Hong Kong Exchanges (HKG), in May 2026 at marketcap of $710M and Broncus got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.26B.

Here are Exome Asset Management's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Impact Therapeutics	May 13, 2026	Mar 14, 2022	Series D	5265
Broncus	Sep 24, 2021	Jan 28, 2021	Series G	9689
Zhejiang Nuhui Health Technology	Feb 18, 2021	Apr 21, 2020	Series D	8201
Aprea	Oct 03, 2019	Mar 11, 2024	Post IPO	7957
NextCure	May 09, 2019	Nov 12, 2025	Post IPO	5050

View more details about public companies in Exome Asset Management's portfolio

1 company from Exome Asset Management's portfolio has been acquired. The most recent acquisition was Gracell Bio in Dec 2023 by AstraZeneca for $*****.

Here are Exome Asset Management's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Gracell Bio	Dec 26, 2023	Aug 07, 2023	Post IPO	2932

View all acquired companies in Exome Asset Management's portfolio

Exome Asset Management has a team of 7 members located in United States. Exome Asset Management's team does not sit on the board of any company as of now.

View team details of Exome Asset Management

Over the past 6 years, 104 investors have co-invested in Exome Asset Management's portfolio companies. This includes only funds.

Invested before Exome Asset Management: Lilly Asia Ventures, 6 Dimensions Capital and 69 others have invested in rounds before Exome Asset Management. There are 3 companies where Lilly Asia Ventures has invested before Exome Asset Management and 3 companies where 6 Dimensions Capital has invested before Exome Asset Management.
Top Co-investors of Exome Asset Management: 24 investors entered a company along with Exome Asset Management. These include investors like Ikarian Capital (1 company).
Invested after Exome Asset Management: A total of 9 investors have invested in Exome Asset Management's portfolio after their investments. Top Investors include ShenZhen GTJA Investment Group (1 company) and Xicheng Jinrui (1 company).